The key to identifying the best therapeutic candidate includes determining binding kinetics (ka & kd) and affinity (KD) of a biologic. Surface Plasmon Resonance (SPR) is the most common way to identify the most promising candidates, and you can utilize SPR in either a low- or high-throughput manner, depending on your inhouse instrumentation. The amount of sample required to perform this analysis differs by your instruments as well.
With SPR, Eurofins Discovery helps you determine the affinity and potency of your molecule by assessing the on-rate (ka) and off-rate (kd). Our scientists then rank your candidate molecules by these measures and work with you to design expanded screening based on those rankings. The affinity of a molecule for the target can also be used to bin molecules if you are trying to narrow down the number of molecules to move forward. If several molecules have similar affinities, they can be binned and a representative molecule from each bin moved forward for further characterization.
At Eurofins Discovery, you don’t have to choose between one approach or platform versus another. With the Carterra LSA and Cytiva Biacore 8K+, Eurofins Discovery offers custom assay development and biotherapeutics characterization augmented by the technical expertise to help you design a biologics discovery project of any size. Our biotherapeutics specialists are with you every step of the way, from assay design, to data delivery and interpretation, giving you confidence in the decisions that will drive your program forward.
Define Potency and Affinity of Your Biologic by SPR
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
